COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2
Brain and Behavior2022Vol. 12(12), pp. e2789–e2789
Citations Over TimeTop 10% of 2022 papers
Syed Muhammad Ismail Shah, Farah Yasmin, Roha Saeed Memon, Nadia Nazir Jatoi, Ilma Saleh Savul, Sana Kazmi, Syed Abdullah Monawwer, Muhammad Daim Bin Zafar, Muhammad Sohaib Asghar, Muhammad Junaid Tahir, Ka Yiu Lee
Abstract
Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.
Related Papers
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → ОПЫТ ОЦЕНКИ ПОПУЛЯЦИОНОГО ИММУНИТЕТА К SARS-CoV-2 СРЕДИ НАСЕЛЕНИЯ ЛЕНИНГРАДСКОЙ ОБЛАСТИ В ПЕРИОД ЭПИДЕМИИ COVID-19(2020)7 cited
- → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited
- → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited